Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice

References

• Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15:16–17
   PubMed Web of Science ®Google Scholar
• Fonia A, Jackson K, Lereun C, et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol. 2010;163:807–16
   PubMed Web of Science ®Google Scholar
• Ferrándiz C, Carrascosa JM, Toro M. Prevalence of psoriasis in Spain in the age of biologics. Actas Dermosifiliogr. 2014;105:504–9
   PubMedGoogle Scholar
• Enbrel Summary of Product Characteristics. Available from http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf. Accessed December 2014
   Google Scholar
• Humira Summary of Product Characteristics. Available from http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf. Accessed December 2014
   Google Scholar
• Remicade Summary of Product Characteristics. Available from http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf. Accessed December 2014
   Google Scholar
• Stelara Summary of Product Characteristics. Available from http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf. Accessed December 2014
   Google Scholar
• Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66:241–51
   PubMed Web of Science ®Google Scholar
• Kimball AB, Papp KA, Wasfi Y, et al; PHOENIX 1 Investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27:1535–45
   PubMed Web of Science ®Google Scholar
• Puig L. Treatment of moderate to severe plaque psoriasis with biologics: analysis of the additional cost of temporary dose escalation vs. switch to another biologic after failure of maintenance therapy. Actas Dermosifiliogr. 2014;105:401–12
   PubMedGoogle Scholar
• Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One. 2012;7:e33486
   PubMed Web of Science ®Google Scholar
• Rivera R, García-Doval I, Carretero G, et al.; Members of the BIOBADADERM Group. BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report. Actas Dermosifiliogr. 2011;102:132–41
   PubMedGoogle Scholar
• Garcia-Doval I, Rustenbach SJ, Stern R, et al. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. Br J Dermatol. 2013;169:710–14
   PubMed Web of Science ®Google Scholar
• Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167:658–67
   PubMed Web of Science ®Google Scholar
• Langley RG. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data? J Eur Acad Dermatol Venereol. 2012;26:21–9
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with Psoriasis vulgaris. Br J Dermatol. 2011;164:1091–6
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85
   PubMed Web of Science ®Google Scholar
• Maneiro JR, Perez-Pampin E, Salgado E, et al. Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. Rheumatol Int. 2014;34:1059–63
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Carretero G, et al; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013 Part 1: on efficacy and choice of treatment. Actas Dermosifiliogr. 2013;104:694–709
   PubMedGoogle Scholar
• Mrowietz U, de Jong EM, Kragballe K, et al. Consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28:438–53
   PubMed Web of Science ®Google Scholar
• Moreno-Ramírez D. Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis. Actas Dermosifiliogr. 2011;102:241–3
   PubMedGoogle Scholar
• Ferrándiz C, García A, Blasco AJ, et al. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2012;26:768–77
   PubMed Web of Science ®Google Scholar
• Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011;12:2041–54
   PubMed Web of Science ®Google Scholar
• Carrascosa JM. Immunogenicity in biologic therapy: implications for dermatology. Actas Dermosifiliogr. 2013;104:471–9
   PubMedGoogle Scholar
• Gordon KB, Gottlieb AB, Leonardi CL, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat. 2006;17:9–17
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of Psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:1–70
   PubMed Web of Science ®Google Scholar